GenPrex, Inc. (GNPX): Modelo de negócios Canvas [Jan-2025 Atualizado]

A GenPrex, Inc. (GNPX) surge como uma empresa pioneira de biotecnologia que revoluciona o tratamento do câncer por meio de tecnologias de terapia genética de ponta. Ao focar em intervenções moleculares inovadoras, particularmente no câncer de pulmão, a empresa representa uma fronteira ousada em pesquisa oncológica, promissora em potenciais tratamentos inovadores para cânceres resistentes a medicamentos. Sua abordagem única combina conhecimentos científicos, plataformas proprietárias e colaborações estratégicas para desenvolver soluções terapêuticas genéticas não invasivas que possam transformar fundamentalmente os resultados dos pacientes no cenário desafiador do tratamento do câncer.

GenPrex, Inc. (GNPX) - Modelo de negócios: Parcerias -chave

Centros médicos acadêmicos e instituições de pesquisa

A GenPrex estabeleceu parcerias com os seguintes centros médicos acadêmicos:

Instituição	Foco de colaboração	Ano estabelecido
MD Anderson Cancer Center	Pesquisa terapêutica oncológica	2019
Centro de Ciências da Saúde da Universidade do Texas	Ensaios clínicos de terapia genética	2020

Colaboradores farmacêuticos e de biotecnologia

As principais parcerias farmacêuticas e de biotecnologia da GenPrex incluem:

• Merck & Co. - Colaboração potencial de imunoterapia
• AstraZeneca - Parceria de Pesquisa de Câncer de Pulmão de Pulmões de Células pequenas
• Pfizer - Avaliação de tecnologia de terapia genética

Organizações de pesquisa contratada (CROs)

Nome do CRO	Serviços prestados	Valor do contrato
Icon plc	Gerenciamento de ensaios clínicos	US $ 2,3 milhões (2023)
Parexel International	Suporte regulatório	US $ 1,7 milhão (2023)

Potenciais investidores estratégicos em terapêutica oncológica

Parcerias de investimento estratégico a partir de 2024:

Investidor	Valor do investimento	Tipo de investimento
Grupo Vanguard	US $ 4,2 milhões	Investimento institucional
BlackRock	US $ 3,8 milhões	Participação em ações

GenPrex, Inc. (GNPX) - Modelo de negócios: Atividades -chave

Desenvolvimento de tecnologias de terapia genética para tratamento de câncer

O GenPrex se concentra no desenvolvimento de tecnologias de terapia genética direcionadas especificamente ao tratamento do câncer. A partir do quarto trimestre 2023, a empresa se concentrou Terapia com imunogeneio Oncoprex® para tratamento de câncer de pulmão.

Foco em tecnologia	Estágio atual	Indicação alvo
Terapia com imunogeneio Oncoprex®	Desenvolvimento Clínico	Câncer de pulmão de células não pequenas

Realização de ensaios clínicos para candidatos inovadores de drogas

A GenPrex está ativamente envolvida em pesquisas de ensaios clínicos para seus candidatos terapêuticos.

• Fase 1/2 Ensaio Clínico para Oncoprex® em Combinação com Keytruda®
• Despesas totais de ensaios clínicos em 2023: US $ 4,2 milhões
• Estudos clínicos em andamento direcionando o câncer de pulmão de células não pequenas metastático

Avançando pesquisas em câncer de pulmão e aplicações de oncologia

Área de pesquisa	Investimento	Foco na pesquisa
Terapia genética de câncer de pulmão	US $ 3,7 milhões (2023)	Estratégia de substituição do gene TUSC2

Desenvolvimento e proteção da propriedade intelectual

O GenPrex mantém um portfólio robusto de propriedade intelectual.

• Total de patentes arquivadas: 12
• Duração da proteção de patentes: até 2038
• Categorias de patentes: terapia genética, metodologias de tratamento de câncer

Conformidade regulatória e interação FDA

Marco regulatório	Status	Data
Designação de pista rápida da FDA	Garantido	Setembro de 2022
Interações FDA em andamento	Comunicação ativa	Consultas trimestrais

GenPrex, Inc. (GNPX) - Modelo de negócios: Recursos -chave

Tecnologia proprietária de plataforma de terapia genética

O principal recurso tecnológico da GenPrex é sua plataforma de terapia de imunogeenos ONCREX®. A partir de 2024, a plataforma se concentra no desenvolvimento de terapias genéticas para tratamento de câncer de pulmão.

Plataforma de tecnologia	Detalhes específicos
Nome da plataforma	Terapia com imunogeneio Oncoprex®
Doença alvo primária	Câncer de pulmão de células não pequenas (NSCLC)
Tipo de tecnologia	Sistema de entrega de terapia genética

Experiência científica em oncologia e terapia genética

O GenPrex mantém uma equipe científica especializada com experiência em pesquisa oncológica de terapia genética.

• Pesquisadores no nível de doutorado especializados em oncologia molecular
• Especialistas em mecanismos de entrega de genes
• Especialistas em desenvolvimento clínico

Portfólio de patentes

Categoria de patentes	Número de patentes	Faixa de validade
Tecnologia de terapia genética central	7 patentes ativas	2030-2036
Mecanismo de entrega	3 patentes especializadas	2032-2037

Infraestrutura de pesquisa e desenvolvimento

Os recursos de P&D da GenPrex estão centrados nas instalações de pesquisa focadas no desenvolvimento da terapia genética.

• Espaço de laboratório: aproximadamente 5.000 pés quadrados.
• Equipamento avançado de biologia molecular
• Cultura de células e instalações de modificação de genes

Equipe científica e médica especializada

Composição da equipe	Número de profissionais
Cientistas de pesquisa	12
Especialistas em desenvolvimento clínico	6
Especialistas em assuntos regulatórios	4

GenPrex, Inc. (GNPX) - Modelo de negócios: proposições de valor

Soluções inovadoras de terapia genética para tratamento de câncer de pulmão

A plataforma de terapia de imunogene ONPREX ™ ONCREX ™ se concentra no fornecimento de genes terapêuticos às células cancerígenas. No quarto trimestre 2023, a empresa relatou ensaios clínicos em andamento para tratamento de câncer de pulmão direcionado aos pacientes com NSCLC (câncer de pulmão de células não pequenas).

Plataforma de terapia	Segmento de paciente alvo	Estágio clínico
Terapia com imunogeene Oncoprex ™	Pacientes avançados de NSCLC	Ensaios clínicos de fase 2

Possíveis tratamentos inovadores para câncer resistente a medicamentos

A abordagem terapêutica da empresa tem como alvo mecanismos de câncer resistentes a medicamentos com intervenções moleculares únicas.

• Mecanismo tem como alvo a restauração do gene TUSC2
• Tratamento potencial para pacientes com câncer de pulmão resistente à quimioterapia
• Mercado endereçável estimado de 228.000 novos casos de câncer de pulmão anualmente nos Estados Unidos

Abordagem terapêutica genética não invasiva

Método de entrega	Principais vantagens	Exclusividade tecnológica
Tecnologia de nanopartículas lipídicas	Minimamente invasivo	Mecanismo de entrega de genes proprietários

Intervenções moleculares direcionadas para pacientes com câncer

A pesquisa da GenPrex se concentra em modificações genéticas precisas com efeitos colaterais sistêmicos mínimos.

• Terapia de reposição de genes direcionados
• Interrupção específica da via molecular
• Redução potencial na toxicidade tradicional da quimioterapia

Potencial para melhorar os resultados dos pacientes

Objetivo terapêutico	Impacto potencial	Status de pesquisa atual
Eficácia do tratamento do câncer de pulmão	Taxas de sobrevivência aprimoradas	Ensaios clínicos em andamento

GenPrex, Inc. (GNPX) - Modelo de negócios: Relacionamentos do cliente

Engajamento direto com a comunidade de oncologia médica

A partir de 2024, o GenPrex mantém estratégias de engajamento direto com profissionais de oncologia médica por meio de interações direcionadas:

Canal de engajamento	Métricas de interação anual
Oncologista Direct Outreach	Aproximadamente 287 profissionais médicos direcionados
Comunicação de pesquisa personalizada	62 centros médicos especializados contatados
Consultas científicas individuais	43 consultas de especialistas individuais

Interações dos participantes do ensaio clínico

O gerenciamento de relacionamento dos participantes do ensaio clínico da GenPrex inclui:

• TOTAL COMPORTIDOS ATIVOS DO TEMBRO CLÍNICO: 124 PACIENTES
• Frequência de comunicação do paciente: atualizações trimestrais de progresso
• Canais de apoio ao paciente: pesquisa de pesquisa de pesquisa dedicada

Apresentações de Conferência Científica e Simpósio Médico

Tipo de conferência	2024 Detalhes da apresentação
Conferências de pesquisa oncológica	7 Principais apresentações internacionais
Simpósios de tecnologia médica	4 fóruns especializados de terapia genética

Comunicação transparente sobre o progresso da pesquisa

As métricas de transparência de comunicação incluem:

• Atualizações trimestrais de investidores/pesquisadores: 4 relatórios abrangentes
• Plataformas de divulgação de pesquisa pública: 12 publicações detalhadas
• Rastreamento de progresso da pesquisa digital: painel online em tempo real

Programas potenciais de apoio ao paciente e educação

Programa de suporte	Alcance do programa
Informações do paciente on -lines	237 participantes registrados
Recursos educacionais online	1.542 visitantes exclusivos do site
Rede de apoio ao paciente	86 conexões de pacientes ativos

GenPrex, Inc. (GNPX) - Modelo de negócios: canais

Comunicação científica direta

A GenPrex utiliza canais de comunicação científica direcionados com os seguintes especificidades:

Canal de comunicação	Freqüência	Público -alvo
Diretor do pesquisador direto	Trimestral	Instituições de Pesquisa Oncológica
Redes de oncologia de precisão	Semestral	Centros de Pesquisa Clínica

Apresentações da conferência médica

Métricas de engajamento da conferência:

• Conferências médicas anuais comparecidas: 7
• Duração média da apresentação: 45 minutos
• Conferências -chave: American Association for Cancer Research (AACR)

Publicações científicas revisadas por pares

Estatísticas de publicação para 2023:

Tipo de publicação	Número	Faixa de fatores de impacto
Artigos de pesquisa originais	3	2.5 - 4.2
Artigos de revisão	2	3.1 - 3.7

Comunicações de Relações com Investidores

Canais de comunicação de investidores:

• Chamadas de ganhos trimestrais
• Reuniões anuais de acionistas
• Decks de apresentação do investidor
• Sec Comunicação de arquivamento

Plataformas digitais e redes científicas

Métricas de engajamento digital:

Plataforma	Seguidores/conexões	Taxa de engajamento
LinkedIn	4,237	2.3%
Twitter	1,892	1.7%

GenPrex, Inc. (GNPX) - Modelo de negócios: segmentos de clientes

Profissionais médicos de oncologia

Em 2024, o GenPrex tem como alvo aproximadamente 16.000 oncologistas nos Estados Unidos, especializados em tratamento de câncer de pulmão.

Foco especial	Número de profissionais -alvo	Penetração potencial de mercado
Oncologistas de câncer de pulmão	16,000	37.5%
Oncologistas de radiação	4,500	22.8%

Instituições de Pesquisa do Câncer

O GenPrex colabora com 62 principais centros de pesquisa de câncer em toda a América do Norte.

• Instituto Nacional do Câncer (NCI) Centros de Câncer Abrangentes Designados: 51
• Centros de Pesquisa Médica Acadêmica: 11

Pacientes com câncer de pulmão

População alvo de pacientes com base em 2024 dados epidemiológicos:

Categoria de pacientes	População total	Candidatos a tratamento em potencial
Câncer de pulmão de células não pequenas	238.340 novos casos	87.456 candidatos em potencial
Câncer de pulmão de pequenas células	31.990 novos casos	11.716 candidatos em potencial

Parceiros de pesquisa farmacêutica

Paisagem de colaboração de pesquisa farmacêutica atual:

• Parcerias de pesquisa ativa: 3
• Discussões de colaboração pendente: 5
• Valor potencial de parceria total: US $ 42,6 milhões

Investidores institucionais em biotecnologia

Análise do segmento de investidores para GenPrex:

Tipo de investidor	Número de investidores institucionais	Investimento total
Empresas de capital de risco	12	US $ 34,2 milhões
Fundos focados em biotecnologia	8	US $ 26,7 milhões
Empresas de investimento em saúde	6	US $ 19,5 milhões

GenPrex, Inc. (GNPX) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a GenPrex relatou despesas de pesquisa e desenvolvimento de US $ 8,4 milhões, em comparação com US $ 7,2 milhões em 2022.

Ano	Despesas de P&D	Variação percentual
2022	US $ 7,2 milhões	-
2023	US $ 8,4 milhões	16.7%

Custos de gerenciamento de ensaios clínicos

A GenPrex alocou aproximadamente US $ 5,6 milhões para gerenciamento de ensaios clínicos em 2023, concentrando -se em sua plataforma de terapia de imunogene Reqorsa ™.

• Ensaios clínicos de fase I/II para tratamento de câncer de pulmão
• Pesquisa em andamento para terapias combinadas
• Despesas de recrutamento e monitoramento de pacientes

Proteção à propriedade intelectual

A empresa gastou US $ 1,2 milhão em proteção de propriedade intelectual e manutenção de patentes em 2023.

Categoria de despesa IP	Quantia
Registro de patentes	$650,000
Manutenção de patentes	$550,000

Despesas de conformidade regulatória

Os custos de conformidade regulatória da GenPrex totalizaram US $ 2,3 milhões em 2023, cobrindo as interações e processos de envio da FDA.

Overhead administrativo e operacional

As despesas administrativas e operacionais totais para 2023 foram de US $ 4,5 milhões, incluindo:

• Salários e benefícios dos funcionários: US $ 3,1 milhões
• Despesas de escritório e instalação: US $ 780.000
• Serviços profissionais: US $ 620.000

Estrutura de custo total para 2023: US $ 21,5 milhões

GenPrex, Inc. (GNPX) - Modelo de negócios: fluxos de receita

Potenciais acordos futuros de licenciamento de medicamentos

A partir de 2024, a GenPrex não relatou acordos ativos de licenciamento de medicamentos. O foco principal da empresa permanece no desenvolvimento de sua plataforma de terapia de imunogene Reqorsa ™.

Bolsas de pesquisa e financiamento do governo

Fonte de financiamento	Quantia	Ano
Institutos Nacionais de Saúde (NIH)	$ 0 (sem subsídios confirmados em 2024)	2024

Colaborações de parceria estratégica

No mais recente relatório financeiro, a GenPrex não divulgou parcerias estratégicas significativas gerando receita direta.

Potencial comercialização terapêutica de produtos

Produto	Estágio atual	Receita potencial
Terapia com imunogene reqorsa ™	Estágio do ensaio clínico	Ainda não comercializado

Oportunidades de monetização da propriedade intelectual

• Portfólio de patentes relacionado à plataforma Reqorsa ™
• Sem receita atual de licenciamento de IP relatado

Dados financeiros do último registro de 10 q: Receita total: US $ 0 para o trimestre encerrado em 30 de setembro de 2023

Informações sobre estoque: Ticker: GNPX Exchange: NASDAQ Capitalização de mercado: aproximadamente US $ 23,5 milhões (em fevereiro de 2024)

Genprex, Inc. (GNPX) - Canvas Business Model: Value Propositions

You're looking at the core value Genprex, Inc. (GNPX) brings to patients and the market as of late 2025. This isn't about future potential alone; it's about the tangible scientific and regulatory milestones they've achieved that define their offering right now.

The primary value proposition centers on novel, first-in-class gene therapies targeting significant unmet needs in oncology. Their lead candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated for Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

The delivery mechanism itself is a key differentiator. Genprex uses its systemic, non-viral Oncoprex® Delivery System, which encapsulates gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. This system is administered intravenously, aiming for safer, targeted uptake by tumor cells.

The regulatory environment validates this approach. Each of Genprex's lung cancer clinical programs has secured an FDA Fast Track Designation for its respective patient population. Furthermore, the SCLC program has an additional FDA Orphan Drug Designation.

The potential market impact is broad, addressing both oncology and metabolic disease. The company is addressing large, unmet needs in NSCLC and SCLC, alongside its preclinical work in diabetes. The diabetes candidate, GPX-002, offers the potential to transform alpha cells into insulin-producing beta-like cells for Type 1 diabetes (T1D).

Here's a snapshot of the current development status underpinning these propositions:

Program Area	Candidate/Platform	Key Status/Data Point (as of late 2025)	Regulatory Status
Oncology (NSCLC/SCLC)	Reqorsa® Gene Therapy (quaratusugene ozeplasmid)	Preclinical data showed a 79% tumor shrinkage in ALK-EML4 positive NSCLC when used with alectinib.	Fast Track Designation for both lung cancer programs. Orphan Drug Designation for SCLC.
Oncology Delivery	ONCOPREX Delivery System	Systemic, non-viral platform using lipid-based nanoparticles.	N/A
Diabetes (T1D/T2D)	GPX-002	Preclinical studies demonstrated sustained improved glucose homeostasis in animal models of T1D.	Preclinical stage; planned to request FDA guidance for IND-enabling studies by the second half of 2025.

The clinical timeline for the lead oncology program shows concrete near-term milestones. The Acclaim-1 Phase 2a portion began dosing in January 2024 and is expected to finish enrolling by the end of 2025. An interim analysis on 19 patients is anticipated in the first half of 2026.

Financially, the company is operating in a capital-intensive phase, which is typical for a clinical-stage biotech. As of late 2025, Genprex had a market capitalization of approximately $6.43 million or $10.8M, with 2.27 million shares outstanding. To support this development, the company secured a registered direct offering of $2.7 million in October 2025, with the potential for another $5.4 million via warrant exercises. Management has been focused on efficiency, trimming operating expenses by 52% year-on-year.

The value proposition is supported by the following strategic elements:

• Novel gene therapy approach for difficult-to-treat cancers.
• Systemic, non-viral delivery platform.
• Preclinical data showing 79% tumor shrinkage in a specific NSCLC model.
• Diabetes program (GPX-002) aiming for alpha cell reprogramming.
• Fast Track Designation for both lung cancer programs.

The company's last reported earnings date was November 14, 2025, with the fiscal year ending December 31, 2025. The stock price as of October 29, 2025, was $6.64.

Genprex, Inc. (GNPX) - Canvas Business Model: Customer Relationships

You're looking at how Genprex, Inc. manages its critical external relationships to advance its gene therapy pipeline. For a clinical-stage biotech, these aren't just contacts; they are the pathways to data, funding, and ultimately, patient access. Here's the breakdown of those key relationship pillars as of late 2025.

High-touch, specialized relationships with key opinion leaders (KOLs) and clinical investigators.

Genprex, Inc. maintains deep ties with the academic and clinical community to drive its two main programs: Reqorsa® Gene Therapy for lung cancer and its diabetes gene therapy approach. These relationships are formalized through research agreements and site activations.

• Collaboration with the University of Michigan Rogel Cancer Center via a Sponsored Research Agreement (SRA) initiated in October 2024.
• New SRA signed with the University of Pittsburgh (Pitt) to study GPX-002 in Type 1 and Type 2 diabetes models.
• The company actively adds clinical sites to support ongoing trials, adding Gabrail Cancer Center in Canton, Ohio, as a new site in November 2025 for the Acclaim-1 and Acclaim-3 trials.

The clinical trial structure dictates specific relationship goals for patient throughput:

Trial Component	Relationship Metric/Target	Status/Target Number
Acclaim-1 Phase 2a Expansion	Expected Patient Enrollment Target	Approximately 33 patients
Acclaim-3 Phase 2 Expansion	Expected Patient Enrollment Target	Approximately 50 patients
Acclaim-1 Interim Analysis Completion	Target for Enrollment of First Patients	First half of 2026 (Enrollment of first 19 patients)

Investor relations for ongoing capital raising and shareholder communication.

Sustaining clinical development requires consistent engagement with capital markets. Genprex, Inc. has been active in securing financing through various equity offerings throughout 2025.

• Announced a $12.5 million commitment from Lincoln Park Capital Fund in June 2025.
• Filed a prospectus in November 2025 to offer up to $75,000,000 in additional common stock shares under its At The Market (ATM) Offering Agreement.
• Previously sold 796,065 shares for aggregate gross proceeds of $14,796,375 under the ATM Sales Agreement.
• Announced a registered direct offering in October 2025, with gross proceeds expected around $2.7 million from the sale of 243,622 shares at $11.21 per share, plus potential proceeds of ~$5.4 million from concurrent warrants.

Direct engagement with patient advocacy groups for trial support.

Genprex, Inc. works with advocacy organizations to align research with patient needs and gain support for specific disease areas.

• Collaboration established in October 2024 with ALK Positive, a non-profit research organization, to sponsor a preclinical study on ALK-EML4 positive lung cancer.
• Research collaborators presented data on the diabetes gene therapy program at the 2025 American Diabetes Association 85th Scientific Sessions.

Regulatory bodies (FDA, EMA) for approvals and designations.

Regulatory interactions are crucial for establishing the accelerated path for its lead candidate, Reqorsa® Gene Therapy.

• Each of Genprex, Inc.'s lung cancer clinical programs has secured Fast Track Designation from the FDA.
• The FDA granted Orphan Drug Designation for Genprex, Inc.'s SCLC program.
• The Acclaim-1 treatment combination (REQORSA and Tagrisso) received Fast Track Designation from the FDA.
• The company announced the European Patent Office's intent to grant a patent for the combination of Reqorsa® Gene Therapy and PD-1 antibodies in November 2025.

Finance: review Q4 2025 ATM utilization against the $75,000,000 shelf capacity by end of day Tuesday.

Genprex, Inc. (GNPX) - Canvas Business Model: Channels

You're looking at how Genprex, Inc. gets its science and its stock in front of the right people-the doctors, the researchers, and the investors. This is all about getting the data out and keeping the lights on through capital markets.

Clinical trial sites and hospitals for drug administration and data collection

The primary channel for drug administration and data collection is the network of clinical trial sites. Genprex, Inc. actively expands this network to ensure patient access and speed up enrollment for its key programs, REQORSA in Acclaim-1 and Acclaim-3 for lung cancer. For instance, on November 19, 2025, Genprex, Inc. announced the addition of Gabrail Cancer Center in Canton, Ohio, as a new site for both the Acclaim-1 and Acclaim-3 clinical trials. The company plans to expand its clinical trial sites to increase patient reach and expedite enrollment. The Acclaim-1 trial targets non-small cell lung cancer, while Acclaim-3 addresses small cell lung cancer. Furthermore, the diabetes gene therapy, GPX-002, is being advanced through preclinical work and new sponsored research, including a new Sponsored Research Agreement with the University of Pittsburgh signed in May 2025 for animal model studies. The delivery method for GPX-002 in humans is designed to be done with a routine endoscopy procedure, suggesting a future channel through specialized gastroenterology or endocrinology centers.

Scientific publications and medical conferences (ASCO, ADA) for data dissemination

Disseminating clinical and preclinical data through peer-reviewed channels and major medical meetings is crucial for validation. Genprex, Inc. has been active in this area throughout 2025. You can see the output of their clinical work appearing in journals and presentations:

• Data from Genprex, Inc.'s Acclaim-1 Phase 1 Gene Therapy Clinical Trial was published in Clinical Lung Cancer on November 24, 2025.
• Genprex, Inc. was selected to present the trial design of the Acclaim-3 Clinical Trial at the 2025 ASCO Annual Meeting.
• Research collaborators presented positive preclinical data on the diabetes gene therapy, GPX-002, at the 2025 American Diabetes Association (ADA) 85th Scientific Session in Chicago in June 2025. The featured abstract was a Poster Presentation in the 20 Beta-Cell Replacement Category, Poster Number 1567-B.
• The company also presented at industry conferences, including the BIO 2025 International Convention in Boston, Mass., from June 16-19, 2025.
• Management participated in investor and industry conferences in September 2025, such as the H.C. Wainwright 27th Annual Global Investment Conference and the Investor Summit Group Q3 Virtual Conference.

Direct investor communications and SEC filings for capital markets

To fund these clinical channels, Genprex, Inc. relies heavily on direct engagement with the capital markets, often utilizing At-The-Market (ATM) offerings and registered direct offerings. This requires constant communication via SEC filings. Here's a snapshot of their capital market activity and status as of late 2025:

Financial/Capital Market Event or Metric	Amount/Value/Date	Source/Context
Maximum Potential Offering Size (Nov 2025)	Up to $75,000,000	Prospectus filed November 21, 2025, under ATM program.
Previous Share Sale Proceeds (Prior to Nov 2025)	$14,796,375	Gross proceeds from the sale of 796,065 shares.
Lincoln Park Capital Commitment (June 2025)	$12.5 million	Commitment for purchasing common stock announced June 11, 2025.
October 2025 Registered Direct Offering Shares Issued	243,622 shares	Issued at a purchase price of $11.21 per share on October 24, 2025.
Registered Direct Offering Announced (Oct 2025)	Up to $10.0 million	Announced on October 28, 2025.
Shares Outstanding (as of Nov 19, 2025)	2,318,894	Reported in an S-1 filing.
Nasdaq Equity Compliance Exception Deadline	December 31, 2025	Deadline to demonstrate long-term compliance with the Stockholders' Equity Requirement.

The company regained compliance with the minimum bid price requirement as of November 25, 2025, but the equity requirement remains on an exception basis. Honestly, managing this cash flow through frequent equity raises is a key channel for survival right now.

Future distribution via pharmaceutical licensing partners

While Genprex, Inc. currently manages its clinical development, the long-term distribution channel for commercial success is expected to involve strategic partnerships. The company explicitly works with world-class institutions and collaborators to develop its pipeline. A significant move signaling this future channel strategy was the September 2024 announcement of the intention to spin off the diabetes program (GPX-002) into a new subsidiary, 'NewCo.' This separation was designed to enhance focus and expedite development, potentially enabling direct investment and strategic collaboration or licensing for the diabetes asset. Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing, was available for one-on-one meetings at the BIO 2025 International Convention to discuss these gene therapies, suggesting active scouting for such future partners. The company's oncology program, utilizing REQORSA, is also being advanced with the expectation of future commercialization pathways, which often involve licensing deals in specific territories or indications.

Finance: draft 13-week cash view by Friday.

Genprex, Inc. (GNPX) - Canvas Business Model: Customer Segments

You're looking at the patient and physician populations that Genprex, Inc. (GNPX) targets with its gene therapy platform, Reqorsa® and GPX-002. It's a dense landscape, especially given the company's TTM Net Income of -21.39M USD as of late 2025.

Patients with Non-Small Cell Lung Cancer (NSCLC) who have progressed on standard therapy.

This segment includes patients with advanced NSCLC, particularly those with EGFR mutations who have exhausted prior lines of therapy. For instance, in the EGFR-mutated advanced NSCLC space, only about half of patients proceed to receive any second-line therapy after progression on first-line osimertinib, creating a significant unmet need for subsequent treatments like Reqorsa®.

For ALK-positive NSCLC, Genprex, Inc. is specifically researching combinations with ALK-inhibitors, targeting a niche within the broader NSCLC market.

Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC).

Genprex, Inc.'s SCLC program has received FDA Orphan Drug Designation, focusing on a highly aggressive patient group. Nearly 60-70% of all Small Cell Lung Cancer patients present with this extensive-stage disease at diagnosis.

The company's Acclaim-1 trial is specifically enrolling ES-SCLC patients who have progressed on Tagrisso-containing regimens. The Phase 2a expansion cohort is expected to enroll approximately 33 patients.

A retrospective study identified 2,025 adult ES-SCLC patients initiating first-line treatment between January 2020 and December 2023, of whom 40% received second-line treatment and 13% received third-line treatment, showing the pool of patients needing novel options.

Patients with Type 1 and Type 2 Diabetes (T1D, T2D) with limited treatment options.

Genprex, Inc. is developing GPX-002 for both Type 1 and Type 2 Diabetes, aiming to restore pancreatic function. The scale of the diabetes population in the U.S. is substantial:

• Total diagnosed diabetes in U.S. adults (18+): 29.4 million.
• Type 2 Diabetes (T2DM) accounts for 90% to 95% of all U.S. diabetes cases.
• Type 1 Diabetes (T1D) in U.S. adults (20+): Approximately 1.7 million.
• Type 1 Diabetes (T1D) in U.S. youth (under 20): 304,000 cases.

Oncologists and endocrinologists seeking novel therapeutic options.

The prescribers and key opinion leaders for these patient populations represent a critical segment for adoption. The numbers for these specialists are as follows:

Specialist Type	Approximate Number in U.S. (Late 2025)	Relevant Context/Data Point
Oncologists (Total Tracked)	Over 28,000	Demand for oncologists is projected to grow by 40% from 2012 to 2025.
Hematology/Oncology Specialists	11,937	This is the most common tracked oncology specialty.
Medical Oncology Specialists	4,778	A key group for NSCLC and SCLC treatment decisions.
Endocrinologists (Total)	10,661	As of November 28, 2025.
Endocrinologists (Actively Treating Diabetes)	Just over 8,000	It is estimated there is a ratio of one endocrinologist to every 5,000 people with diabetes.

Honestly, you see the concentration issue right away; 70% of U.S. counties have no endocrinologist, which means Genprex, Inc.'s diabetes approach, if successful, could be highly attractive to the specialists who do practice, as they manage a disproportionately large patient load.

Genprex, Inc. (GNPX) - Canvas Business Model: Cost Structure

You're analyzing the cost base for Genprex, Inc. (GNPX) as it pushes its gene therapy platform through late-stage clinical development. For a clinical-stage biotech, the cost structure is overwhelmingly weighted toward research and development, which is the engine funding the pipeline.

The dominant cost driver is clearly Research & Development (R&D) expenses, which directly fund the ongoing Acclaim-1 and Acclaim-3 clinical trials for REQORSA. For the second quarter of 2025, the reported R&D expense was $2.50 million. This expense category absorbs the majority of the cash burn required to advance the lead candidate.

The total operating cost for the period reflects this heavy investment. Total operating expenses for Q2 2025 were reported at $4.68 million. This figure encapsulates the R&D spend along with the necessary overhead to support those trials.

The remaining costs fall under General and Administrative (G&A) and third-party vendor expenses. Genprex, Inc. explicitly relies on external partners, such as contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs), for scaling up clinical production and executing trials. Furthermore, legal and patent costs are a constant in this sector, especially following recent patent grants in late 2025 for the Reqorsa® combination therapy.

Here is a look at the key components of the cost structure based on the Q2 2025 figures:

Cost Component	Q2 2025 Amount (USD)
Dominant R&D Expenses	$2,500,000
General & Administrative (G&A) Overhead (Including Legal/Patent)	To be determined from remainder
Manufacturing & Third-Party Vendor Expenses (CRO/CDMO)	To be determined from remainder
Total Operating Expenses	$4,680,000

The non-R&D operating costs, which include G&A and vendor expenses, must account for the difference between the total operating expense and the reported R&D figure. This remaining amount, $2.18 million, covers the essential infrastructure to run the business and manage external partnerships.

You should track these specific cost elements closely, as they represent the operational efficiency outside of the core drug development:

• R&D expenses were $2.50 million for Q2 2025.
• Total operating expenses for Q2 2025 were $4,680,000.
• The company maintains partnerships with third-party vendors for clinical production scale-up.
• Legal and patent protection costs are ongoing, evidenced by recent patent activity in late 2025.
• The net loss for the nine months ended September 30, 2025, was $12.44 million, showing a reduction trend.

Finance: draft 13-week cash view by Friday.

Genprex, Inc. (GNPX) - Canvas Business Model: Revenue Streams

You're looking at Genprex, Inc. (GNPX) and trying to map out where the money comes from. Honestly, for a clinical-stage gene therapy company like this, the revenue stream section of the Business Model Canvas is almost entirely about capital formation, not product sales, at least as of late 2025.

The most direct takeaway for the 2025 fiscal year is that Genprex, Inc. is still firmly in the pre-revenue stage. For the trailing twelve months (TTM) ending September 30, 2025, Genprex, Inc. reported $0.0 in total revenue. This means revenue from product sales is effectively $0 for the 2025 fiscal year. This is defintely standard for a company focused solely on Research and Development (R&D) and clinical progression.

The primary cash source keeping the lights on and funding the clinical trials is equity financing. The company is actively tapping capital markets to fund its operations, which saw an operating cash outflow of $11.21 million for the nine months ended September 30, 2025. Here's the quick math on the financing activity seen in late 2025:

• Financing activities generated approximately $7.77 million in net cash for the six months ended June 30, 2025.
• The company raised $10.71 million through equity offerings in 2025 up to the Q3 report.
• In June 2025, Genprex, Inc. secured a $12.5 million commitment from Lincoln Park Capital Fund.
• Around October 2025, Genprex, Inc. announced a registered direct offering and concurrent private placement that could potentially raise up to $10.0 million in gross proceeds if all warrants are fully exercised on a cash basis.

This reliance on external capital is the current reality of the business model, as shown by the cash position as of September 30, 2025, which stood at only $1.10 million. The company carries a 'going concern' disclosure, underscoring this dependency.

Potential future revenue streams are entirely contingent on clinical success, which is where the long-term value proposition lies. These streams are not generating cash now but are the ultimate goal:

Future revenue is anticipated from:

• Milestone payments tied to clinical trial progression (e.g., completion of Acclaim-1 or Acclaim-3).
• Licensing agreements for its lead candidate, Reqorsa® Gene Therapy, or its diabetes gene therapy, GPX-002.
• Royalties from future commercial sales post-regulatory approval.

Grants and sponsored research income remain minimal or non-existent as a direct revenue line in the TTM period, though the activity confirms the stream's existence. Genprex, Inc. has engaged in agreements that represent future collaboration or research support, rather than immediate cash inflow:

Research/Grant Activity	Date Announced	Focus Area
New Sponsored Research Agreement (SRA)	May 7, 2025	GPX-002 for Type 1 and Type 2 Diabetes (with University of Pittsburgh)
Sponsored Research Agreement (SRA)	October 2024	REQORSA in combination with ALK-inhibitors (with University of Michigan Rogel Cancer Center)

So, you're funding the pipeline now, hoping for licensing fees and royalties later.